Cite
MLA Citation
Mark Agulnik et al.. “An open-label single-arm phase II study of regorafenib for the treatment of angiosarcoma.” European journal of cancer, vol. 154, 2021, pp. 201–208. http://access.bl.uk/ark:/81055/vdc_100139915744.0x00003a